Investigational drug · Phase 3
CardiolRx
Also called: Pharmaceutically produced cannabidiol
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Recurrent Pericarditis, Acute Myocarditis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "CardiolRx"
First trial start
2022
Jul 28, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CardiolRx", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Pericarditis
- Acute Myocarditis
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CardiolRx" as an intervention, largest first.
- CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Pivotal-lookingRecruiting
Cardiol Therapeutics Inc.Industry
NCT06708299 · 110 participants (planned) · Start Apr 7, 2025 · Primary completion Sep 21, 2026
Drug: CardiolRx · For: Recurrent Pericarditis
Sites: Phoenix, Arizona; Irvine, California; La Jolla, California · 27 sites in all
- Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisPivotal-lookingCompleted
Cardiol Therapeutics Inc.Industry
NCT05180240 · 109 participants · Start Jul 28, 2022 · Primary completion Jan 31, 2025
Drug: CardiolRx · For: Acute Myocarditis
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Minneapolis, Minnesota · 37 sites in all
- Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsPivotal-lookingTerminated
Cardiol Therapeutics Inc.Industry
NCT04615949 · 90 participants · Start Apr 30, 2021 · Primary completion Nov 30, 2022
Drug: Cannabidiol, pharmaceutically produced with < 5 ppm THC; Placebo · For: COVID-19; Cardiovascular Diseases; Cardiovascular Risk Factor
Sites: Phoenix, Arizona; Cutler Bay, Florida; Miami, Florida · 20 sites in all
Cardiol Therapeutics Inc.Industry
NCT05494788 · 27 participants · Start Jan 9, 2023 · Primary completion Jun 15, 2024
Drug: CardiolRx · For: Recurrent Pericarditis
Sites: Tucson, Arizona; Washington D.C., District of Columbia; Boston, Massachusetts · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options.
Imazio M, Collini V, Venturelli F, et al. · Expert Opin Emerg Drugs 2026
- Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study.
McNamara DM, Cooper LT, Friedrich MG, et al. · ESC Heart Fail 2026
- Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: Rationale & design of the ARCHER trial.
McNamara DM, Cooper LT, Arbel Y, et al. · ESC Heart Fail 2024
Also in development for Recurrent Pericarditis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.